谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK Plus NSCLC from the ALTA-1L Trial

M. -J. Ahn, A. Delmonte, S. Ghosh,M. Hochmair,T. -Y. Yang,J. C. -H. Yang,J. -Y. Han,K. Holmskov Hansen, Y. Wu, Y. Wan,H. M. Lin, J. Kretz, B. Hupf, A. M. Kurec,E. N. Churchill,R. J. Fram, C. J. Cabasag, V. Goriya, Y. Zhao, E. Gemmen,M. R. Garcia Campelo

JOURNAL OF THORACIC ONCOLOGY（2024）

引用 0|浏览0
关键词
Brigatinib,ALK plus NSCLC,ALK TKI
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要